Original language | English |
---|---|
Pages (from-to) | 163-168 |
Number of pages | 6 |
Journal | Journal of the Canadian Urological Association |
Volume | 14 |
Issue number | 6 |
DOIs | |
Publication status | Published - Apr 2020 |
Externally published | Yes |
ASJC Scopus Subject Areas
- Urology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of the Canadian Urological Association, Vol. 14, No. 6, 04.2020, p. 163-168.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - A canadian framework for managing prostate cancer during the COVID-19 pandemic
T2 - Recommendations from the canadian urologic oncology group and the canadian urological association
AU - Kokorovic, Andrea
AU - So, Alan I.
AU - Hotte, Sebastien J.
AU - Black, Peter C.
AU - Danielson, Brita
AU - Emmenegger, Urban
AU - Finelli, Antonio
AU - Niazi, Tamim
AU - Pouliot, Frederic
AU - Shayegan, Bobby
AU - Sridhar, Srikala
AU - Vigneault, Eric
AU - Loblaw, Andrew
AU - Rendon, Ricardo A.
N1 - Funding Information: Inc, Bayer, Eisai Canada, and Janssen Oncology; has had a consulting or advisory role with Astellas Pharma; AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Janssen, Merck, Pfizer, and Roche Canada; has received research funding from AstraZeneca, Ayala Pharmaceuticals, Bayer, Bristol-Myers Squibb, Clovis Oncology, Janssen Oncology, Merck, Pfizer (Inst), and Roche/Genentech; and has received travel, accommodations, and expenses from Eisai Canada. Dr. Black has been advisory board member or equivalent for Abbvie, Asieris, Astellas, AstraZeneca, Bayer, Biosyent, BMS, EMD-Serono, Fergene, H3-Biomedicine, Janssen, Merck, Roche, Sanofi, and Urogen; a speakers’ bureau member for Abbvie, Biosyent, Ferring, Janssen, Pfizer, and TerSera; has received grants and/or honoraria from Bayer, GSK, iProgen, and Sanofi; has participated in clinical trials supported by Astellas, AstraZeneca, BMS, Genentech, Janssen, MDx Health, Pacific Edge, Sitka, and Therelase; and shares a patent with Decipher Biosciences. Dr. Danielson has received advisory board honoraria and speaker fees from Amgen, Astellas, Bayer, and Janssen. Dr. Emmenegger. Dr. Finelli has been an advisory board member for Abbvie, Astellas, Bayer, Janssen, Ipsen, Sanofi, and TerSera; and has participated in clinical trials supported byAstellas, Bayer, and Janssen. Dr. Niazi has received research grants and honoraria from Abbvie, Amgen, Astellas, Astra Zeneca, Bayer, Janssen, and Sanofi; and has participated in clinical trials supported by Astellas, Ferring, Janssen, and Sanofi. Dr. Pouliot has been an advisory board member for Amgen, Astellas, Bayer, and Janssen; has received payment from Abbott, Amgen, Astellas, Astra Zeneca, Bayer, Ferring, Janssen, and Sanofi; has received grants from Astra Zeneca and Sanofi; and has participated in clinical trials supported by Astellas, Bayer, Ferring, and Janssen. Dr. Shayegan has been an advisory board member for Astellas, Bayer, and Janssen; and has received a research grant from Janssen. Dr. Sridhar has been an advisory board member for Astellas, AstraZeneca, Bayer, Janssen, Merck, and Roche; and has participated in several pharma-supported clinical trials. Dr. Vigneault has been an advisory board member for Abbvie, Bayer, Ferring, and Sanofi. Dr. Loblaw has been an advisory bpard members for Abbvie, Amgen, Astellas, Janssen, and Sanofi; and has received honoraria from AbbVie, Astellas, Amgen, AstraZeneca, Bayer, Janssen, Sanofi, and TerSera. Dr. Rendon has been an advisory board and speakers’ bureau member for, and has received honoraria from Abbvie, Amgen, Astellas, Astra Zeneca, Bayer, Ferring, Jansen, and Sanofi.
PY - 2020/4
Y1 - 2020/4
UR - http://www.scopus.com/inward/record.url?scp=85088261139&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088261139&partnerID=8YFLogxK
U2 - 10.5489/CUAJ.6667
DO - 10.5489/CUAJ.6667
M3 - Article
AN - SCOPUS:85088261139
SN - 1911-6470
VL - 14
SP - 163
EP - 168
JO - Journal of the Canadian Urological Association
JF - Journal of the Canadian Urological Association
IS - 6
ER -